DK0661060T3 - Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling - Google Patents

Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling

Info

Publication number
DK0661060T3
DK0661060T3 DK94120595T DK94120595T DK0661060T3 DK 0661060 T3 DK0661060 T3 DK 0661060T3 DK 94120595 T DK94120595 T DK 94120595T DK 94120595 T DK94120595 T DK 94120595T DK 0661060 T3 DK0661060 T3 DK 0661060T3
Authority
DK
Denmark
Prior art keywords
preparation
high concentrated
concentrated immunoglobulin
immunoglobulin
highly concentrated
Prior art date
Application number
DK94120595T
Other languages
English (en)
Inventor
Yendra Dr Linnau
Johann Dr Eibl
Wolfgang Dr Teschner
Original Assignee
Baxter Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=6506449&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0661060(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Baxter Ag filed Critical Baxter Ag
Application granted granted Critical
Publication of DK0661060T3 publication Critical patent/DK0661060T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK94120595T 1993-12-28 1994-12-23 Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling DK0661060T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4344824A DE4344824C1 (de) 1993-12-28 1993-12-28 Hochkonzentriertes Immunglobulin-Präparat und Verfahren zu seiner Herstellung

Publications (1)

Publication Number Publication Date
DK0661060T3 true DK0661060T3 (da) 2001-07-30

Family

ID=6506449

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94120595T DK0661060T3 (da) 1993-12-28 1994-12-23 Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling

Country Status (15)

Country Link
US (1) US5608038A (da)
EP (1) EP0661060B1 (da)
JP (1) JP3040678B2 (da)
AT (2) AT407707B (da)
CA (1) CA2138853A1 (da)
CZ (1) CZ284186B6 (da)
DE (2) DE4344824C1 (da)
DK (1) DK0661060T3 (da)
ES (1) ES2158877T3 (da)
FI (1) FI111224B (da)
HR (1) HRP941018B1 (da)
HU (1) HU220766B1 (da)
NO (1) NO315260B1 (da)
RU (1) RU2104713C1 (da)
YU (1) YU77994A (da)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA966075B (en) * 1995-07-27 1998-01-19 Genentech Inc Protein formulation.
AU716785B2 (en) * 1995-07-27 2000-03-09 Genentech Inc. Stabile isotonic lyophilized protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
GB9610992D0 (en) 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
AU740284B2 (en) * 1997-06-13 2001-11-01 Genentech Inc. Stabilized antibody formulation
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6991790B1 (en) 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
SI1324776T2 (en) * 2000-10-12 2018-06-29 Genentech, Inc. Concentrated protein formulations with reduced viscosity
US7425618B2 (en) * 2002-06-14 2008-09-16 Medimmune, Inc. Stabilized anti-respiratory syncytial virus (RSV) antibody formulations
US7132100B2 (en) 2002-06-14 2006-11-07 Medimmune, Inc. Stabilized liquid anti-RSV antibody formulations
CN1671741A (zh) * 2002-06-21 2005-09-21 拜奥根Idec公司 浓缩抗体的缓冲剂制剂及其使用方法
US20040033228A1 (en) 2002-08-16 2004-02-19 Hans-Juergen Krause Formulation of human antibodies for treating TNF-alpha associated disorders
MY150740A (en) * 2002-10-24 2014-02-28 Abbvie Biotechnology Ltd Low dose methods for treating disorders in which tnf? activity is detrimental
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US20050158303A1 (en) * 2003-04-04 2005-07-21 Genentech, Inc. Methods of treating IgE-mediated disorders comprising the administration of high concentration anti-IgE antibody formulations
AU2004229335C1 (en) 2003-04-04 2010-06-17 Genentech, Inc. High concentration antibody and protein formulations
BRPI0513601A (pt) * 2004-07-23 2008-05-13 Genentech Inc métodos de produção de cristais de anticorpo ou seu fragmento, composições, formulação, cristal de anticorpo ou seu fragmento, método de tratamento e métodos de produção de cristais e de gel de proteìna de anticorpo ou seu fragmento
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
KR20080031684A (ko) 2005-06-14 2008-04-10 암젠 인코포레이티드 자가 - 완충성 단백질 제형
US20070190057A1 (en) 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
AR059066A1 (es) 2006-01-27 2008-03-12 Amgen Inc Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf)
CA2681752A1 (en) 2007-03-29 2008-10-09 Abbott Laboratories Crystalline anti-human 1l-12 antibodies
CA2707483A1 (en) * 2007-11-30 2009-06-11 Wolfgang Fraunhofer Protein formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
TWI489994B (zh) * 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
NZ592644A (en) * 2008-11-28 2013-09-27 Abbott Lab Stable antibody compositions and methods for stabilizing same
US20100158893A1 (en) * 2008-12-19 2010-06-24 Baxter International Inc. Systems and methods for obtaining immunoglobulin from blood
SG174258A1 (en) * 2009-03-06 2011-10-28 Genentech Inc Antibody formulation
JP5734985B2 (ja) 2009-09-17 2015-06-17 バクスター・ヘルスケヤー・ソシエテ・アノニムＢａｘｔｅｒ Ｈｅａｌｔｈｃａｒｅ ＳＡ ヒアルロニダーゼおよび免疫グロブリンの安定な共製剤およびそれらの使用方法
BR112012022258A2 (pt) 2010-03-01 2016-10-25 Bayer Healthcare Llc anticorpos monoclonais otimizados contra inibidor de trajetória de fator de tecido ( tfpi)
FR2994390B1 (fr) 2012-08-10 2014-08-15 Adocia Procede d'abaissement de la viscosite de solutions de proteines a concentration elevee
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
AU2013203043B2 (en) 2013-03-15 2016-10-06 Takeda Pharmaceutical Company Limited Methods to produce a human plasma-derived igg preparation enriched in brain disease-related natural iggs
EP3808338A1 (en) 2013-09-11 2021-04-21 Eagle Biologics, Inc. Liquid protein formulations containing ionic liquids
ES2875878T3 (es) 2013-11-18 2021-11-11 Formycon Ag Composición farmacéutica de un anticuerpo anti-VEGF
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
US20160074515A1 (en) 2014-06-20 2016-03-17 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
RU2599029C1 (ru) * 2015-07-16 2016-10-10 Игорь Геннадьевич Ковшик Химерный иммуноглобулиновый препарат, обладающий специфическим противовирусным или антибактериальным действием
ES2964640T3 (es) 2015-08-13 2024-04-08 Amgen Inc Filtración en profundidad cargada de proteínas de unión al antígeno
BR112019007858A2 (pt) 2016-10-21 2019-07-02 Amgen Inc formulações farmacêuticas e métodos para produzir as mesmas

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4075193A (en) * 1976-11-26 1978-02-21 Parke, Davis & Company Process for producing intravenous immune globulin
AT359641B (de) * 1978-09-19 1980-11-25 Immuno Ag Verfahren zur herstellung eines intravenoes ver- abreichbaren antikoerperhaeltigen immunglobulin- praeparates
US4186192A (en) * 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
JPS57203017A (en) * 1981-06-09 1982-12-13 Fujirebio Inc Purifying method of immunoglobulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
DK166763B1 (da) * 1983-03-16 1993-07-12 Immuno Ag Immunoglobulin-g-holdig fraktion
DE3483784D1 (de) * 1984-07-07 1991-01-31 Woelm Pharma Gmbh & Co Verfahren zur herstellung von gamma-globulin zur intravenoesen anwendung.
JPH0825902B2 (ja) * 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
DE3619565A1 (de) * 1986-06-11 1987-12-17 Behringwerke Ag Verfahren zur herstellung einer pasteurisierten immunglobulinpraeparation
US5248767A (en) * 1986-06-11 1993-09-28 Behringwerke Aktiengesellschaft Process for the preparation of a pasteurized immunoglobulin preparation using ethanol
DE3825429C2 (de) * 1988-07-27 1994-02-10 Biotest Pharma Gmbh Verfahren zur Herstellung eines intravenös verabreichbaren polyklonalen Immunglobulin-Präparates mit hohem IgM-Gehalt
CH684164A5 (de) * 1992-01-10 1994-07-29 Rotkreuzstiftung Zentrallab Intravenös anwendbare Immunglobulinlösung.

Also Published As

Publication number Publication date
JP3040678B2 (ja) 2000-05-15
FI946104A (fi) 1995-06-29
HUT70449A (en) 1995-10-30
ES2158877T3 (es) 2001-09-16
US5608038A (en) 1997-03-04
CA2138853A1 (en) 1995-06-29
NO315260B1 (no) 2003-08-11
FI946104A0 (fi) 1994-12-27
RU2104713C1 (ru) 1998-02-20
YU77994A (sh) 1997-03-07
HU9403795D0 (en) 1995-02-28
NO945045L (no) 1995-06-29
DE59409761D1 (de) 2001-06-28
HRP941018B1 (en) 1999-12-31
EP0661060B1 (de) 2001-05-23
EP0661060A2 (de) 1995-07-05
CZ328494A3 (en) 1995-07-12
FI111224B (fi) 2003-06-30
NO945045D0 (no) 1994-12-27
DE4344824C1 (de) 1995-08-31
JPH07206709A (ja) 1995-08-08
EP0661060A3 (de) 1997-01-15
HU220766B1 (hu) 2002-05-28
CZ284186B6 (cs) 1998-09-16
ATA237894A (de) 2000-10-15
HRP941018A2 (en) 1997-04-30
AT407707B (de) 2001-05-25
ATE201328T1 (de) 2001-06-15

Similar Documents

Publication Publication Date Title
DK0661060T3 (da) Højkoncentreret immunglobulinpræparat og fremgangsmåde til dets fremstilling
IS4185A (is) Hliðstæð aðferð til framleiðslu fenýlsúlfonylamino-pýrimidines afleiða
AU5612694A (en) Injectable composition
YU47204B (sh) Derivati didehidro-vitamina d3
KR870003793A (ko) 트롬빈 제재의 방법
PL314187A1 (en) Novel derivatives of pyrazine carboxamide, method of obtaining them and their application in pharmaceutical composition
DE3682208D1 (de) Gegenueber lichteinfluss stabilisiertes nifedipin-konzentrat und verfahren zu seiner herstellung.
ES2072784T3 (es) Benzo- y piridopiridonas substituidas con sulfonilbencilo.
AU5652796A (en) Solid compositions containing polyethyleneoxide and a non-am orphous active principle
DK0638068T3 (da) Fremgangsmåde til fremstilling af (S)-3-amino-1-substitueret-pyrrolidiner
AU6593094A (en) Fuel additives
FR2701580B1 (fr) Procédé d'administration d'applications avec des protocoles standards.
DE59709731D1 (de) Niedrigviskose Polyisocyanatmischung
AU8375891A (en) Antioxidant system based on a basic amino acid in combination with a tocopherol or derivative thereof and a nonthiolated polypeptide, and compositions containing the same
DK1128820T3 (da) Farmaceutisk blanding omfattende en kombination af en profen og andre aktive forbindelser
KR830010091A (ko) 구연산 나프티드로푸릴의 제조방법
AU1508592A (en) Sweetening agents derived from l-glutamic acid and their method of preparation
BR0208347A (pt) Compostos de antraquinona auto-redutores
PL312966A1 (en) Derivatives of thiocarbamoil
KR900018123A (ko) 광학적 활성인 d-2-n-펜아세틸아미노-4-메틸 포스피노부티르산의 라세미화 방법
TW362019B (en) Stable preparation of sodium 1,4-dimethylisopropylazulene-3-sulfonate and process thereof
KR870008535A (ko) "밤"가루(율분)
HUT35652A (en) Process for production of veterinary composition containing sulphamids suitable against illnesses caused by pathogene coli stocks
KR930003920A (ko) 스테비아계 내복액 및 그 제조방법
KR910009258A (ko) 니트록시닐과 레바미솔 복합주사제의 제조방법